This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

China Stroke Primary Prevention Trial (CSPPT)

This study has been completed.
Anhui Medical University
Information provided by (Responsible Party):
Shenzhen Ausa Pharmed Co.,Ltd Identifier:
First received: November 19, 2008
Last updated: August 11, 2014
Last verified: August 2014
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.

Condition Intervention Phase
Primary Hypertension Drug: Enalapril/folic acid Drug: Enalapril maleate Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.

Resource links provided by NLM:

Further study details as provided by Shenzhen Ausa Pharmed Co.,Ltd:

Primary Outcome Measures:
  • First attack of symptomatic stroke ( ischemic or hemorrhagic) [ Time Frame: during the trial period ]
    Patients are followed-up every 3 months. All endpoint outcomes are assessed by the Endpoint Adjudication Committee of the study.

Secondary Outcome Measures:
  • Composite major cardiovascular events [ Time Frame: during the trial period ]
  • All-cause death [ Time Frame: during the trial period ]
  • First attack of ischemic stroke and resultant death [ Time Frame: during the trial period ]
  • First attack of hemorrhagic stroke and resultant death [ Time Frame: during the trial period ]
  • Myocardial infarction and resultant death [ Time Frame: during the trial period ]

Other Outcome Measures:
  • Malignant tumors [ Time Frame: during the trial period ]

Enrollment: 20702
Study Start Date: May 2008
Study Completion Date: June 2014
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Enalapril/folic acid
A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
Drug: Enalapril/folic acid
Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Other Name: Enalapril Maleate and Folic Acid Tablet
Active Comparator: Enalapril
Enalapril maleate 10 mg per day is given
Drug: Enalapril maleate
Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
Other Name: Lameiya,Yabao Pharmaceutical

Detailed Description:

Primary hypertension is the most important risk factor leading to cardiovascular events. Successful management of hypertension is a key to prevent these events. Hyperhomocysteinemia (HHcy) is another independent risk factor, especially for stroke. Our team's prospective nested case-control study of 39165 subjects in China showed that incidence of cardiovascular events (especially stroke) was strongly associated with plasma level of total homocysteine (tHcy). The coexistence of hypertension and HHcy dramatically increased the risk of stroke by 25 to 30 times as compared to the subjects without the two risk factors (Graham et al, 1997). Findings from previous and our studies clearly indicate that simultaneous control of hypertension and HHcy is pivotal in reducing cardiovascular events morbidity and mortality in China.

It has been well documented that folic acid is effective in lowering the level of plasma tHcy. While controversial remains on its efficacy on preventing cardiovascular events, a study done by our team: "Efficacy of folic acid supplementation in stroke prevention: a meta-analysis" (Wang et al, 2007) provide coherent evidence that folic acid supplementation can decrease the risk of stroke by 18%, and 25% in populations where folic fortification was not issued, or used for primary prevention.

C677T gene polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) is one of the genetic determinators of plasma tHcy level. Observational studies showed that individuals with TT genotype tend to have high plasma tHcy and elevated risk of cardiovascular events (Cronin et al. 2005), and folic acid supplementation led to a remarkable reduction in plasma tHcy. In short, previous studies by others and by our team have provided strong rationale for our proposed trial as detailed below.

The hypothesis of the current study is that a combination of antihypertensive drug (e.g., enalapril) with folic acid is not only efficacious, but also is safe and highly cost-effective than antihypertensive (e.g., enalapril) used alone to prevent stroke in hypertensive patients.

This trial will enroll 20,000 patients with primary hypertension and with known MTHFR C677T genotype. Subjects will be first stratified by genotypes, and then randomly assigned to treatment groups. The study patients will be instructed to take orally enalapril 10 mg daily or enalapril/folic acid 10mg/0.8mg tablets daily for a maximum of 5 years. The follow-up is given every 3 months.

The incidence and time of first-time stroke episode (primary endpoint) or composite cardiovascular events are used as endpoints. They will be compared by treatment groups with and without stratification by C677T gene polymorphisms. The potential interaction between treatment groups and C677T gene polymorphisms on therapeutic efficacy will also be tested.

This will be the first and largest trial of this kind in Chinese population. The findings from this trial may have the potential to transform current clinical and public health findings into practice.


Ages Eligible for Study:   45 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • BP≥140/90 mmHg in both of the two screening visits or currently under anti-hypertension treatment
  • 45 - 75 years old
  • Successful determination of MTHFR C677T genotype
  • For pre-menopausal women, agreed to use contraceptives during the trial
  • Signed the written informed consent

Exclusion Criteria:

  • Having a history of stroke
  • Having a history of myocardial infarction
  • Having a history of physician diagnosed heart failure
  • Post- coronary revascularization
  • Severe somatic disease such as cancer
  • Secondary hypertension
  • Congenital or acquired organic heart diseases
  • Contraindicated to angiotensin-converting enzyme inhibitor(ACEI)
  • History of ACEI adverse effects
  • Currently long-term use of folic acid or vitamin B12 or vitamin B6
  • Pregnant or child breastfeeding women
  • Severe mental disorders
  • Lab tests indicating abnormal liver or kidney function
  • Unwilling to participate the trial, unwilling to change the current antihypertensive treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00794885

China, Anhui
Anqing Branch, Anhui Institute of Biomedical Research
Anqing City, Anhui, China, 246000
China, Jiangsu
Lianyungang Center for Advanced Research in Cardiovascular Diseases
Lianyungang, Jiangsu, China, 222003
Sponsors and Collaborators
Shenzhen Ausa Pharmed Co.,Ltd
Anhui Medical University
Principal Investigator: Yong Huo, M.D. The First Hospital, Beijing University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Shenzhen Ausa Pharmed Co.,Ltd Identifier: NCT00794885     History of Changes
Other Study ID Numbers: Ausa-CSPPT
Study First Received: November 19, 2008
Last Updated: August 11, 2014

Keywords provided by Shenzhen Ausa Pharmed Co.,Ltd:
cardiovascular events
folic acid
randomized controlled trial
MTHFR C677T genotype

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Folic Acid
Vitamin B Complex
Maleic acid
Growth Substances
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Antihypertensive Agents processed this record on September 19, 2017